The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
As technology continues to evolve, the trajectory for MIS in ASCs remains positive. With continued innovation, procedural migration, and improved patient selection, the next decade is poised to bring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback